Cynata Therapeutics Ltd., of Melbourne, Australia, said that the eighth participant has been dosed in its first trial of the mesenchymal stem cell product CYP-001 for the treatment of steroid-resistant graft-vs.-host disease, marking the halfway point for recruitment into the study. An independent data safety monitoring board review will be triggered once the patient reaches day 28 of the study.